Pfizer announced topline data from one of its phase 3 studies for 20vPnC for the prevention of invasive disease and pneumonia.
Anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy in addition to standard pneumonia therapy does not improve mortality.
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
The FDA has requested that all manufacturers of bacitracin for injection voluntarily withdraw their product from the market.
As of Jan. 2, 2020, 41 patients were admitted with laboratory-confirmed 2019 novel coronavirus (2019-nCoV), all of whom had pneumonia.
Patients with both COPD and chronic bacterial infection who had <100 circulating eosinophils/µL were at high risk of developing pneumonia.
Biomarker-guided exclusion of ventilator-associated pneumonia was not associated with a reduction in antibiotic use.
Inhaled amikacin adjunctive to standard-of-care intravenous antibiotic therapy was not associated with improvements in survival in mechanically ventilated patients with Gram-negative pneumonia.
Microbiologic treatment failure was found to be independently associated with recurrent pneumonia or death among patients with bacterial pneumonia after clinical cure.
The first death in an outbreak of a new type of coronavirus was announced Saturday by officials in the central Chinese city of Wuhan.
A new type of coronavirus may be responsible for dozens of viral pneumonia illnesses in China.
Data gathered from a meta-analysis of clinical practice guidelines published in the European Journal of Clinical Microbiology and Infectious Diseases, show that well-designed randomized controlled trials are urgently needed.
Exposure to carbapenem and carboxypenicillin or ureidopenicillin during the week before onset of ventilator-associated pneumonia and the severity of disease with regard to respiratory and hematologic failures were independent risk factors for the occurrence of Stenotrophomonas maltophilia-related VAP.
The incidence of invasive pneumococcal disease (IPD) is >7-times higher in people living with HIV (PLWHIV) compared with the general population.
The objective surveillance for nonventilator hospital-acquired pneumonia (HAP) via electronically computable definitions generates incidence, mortality, and adjusted odds ratios [OR] for hospital mortality similar to those generated by manual surveillance.
The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.
The development of respiratory syncytial virus (RSV) bronchiolitis in infants within the first 6 months of life was associated with increased odds of pneumonia, otitis media, and filling of antibiotic prescriptions in the second 6 months of life, according to study results published in Clinical Infectious Diseases. This was a population-based cohort study of infants…
Early-onset pneumonia with multidrug-resistant organisms is a major concern for patients who have received a liver transplant, and pre- and intra-operative risk factors influence its development, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting, held November 8 to 12, 2019 in Boston, Massachusetts. In an…
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
The FDA has approved the supplemental NDA for Baxdela for the treatment of community acquired bacterial pneumonia in adult patients.